Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research
NEW YORK, Oct. 8, 2025 — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological, oncological disorders, today announced it has expanded its artificial intelligence (AI) initiative through a new NVIDIA AI Enterprise subscription license to accelerate data-driven drug development, preclinical modeling, and predictive analytics.
Under the new entitlement and renewal agreement, Hoth Therapeutics has secured annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research.
“Our continued investment in NVIDIA’s AI platform reflects our long-term commitment to integrating next-generation technology across our R&D programs,” said Robb Knie, CEO of Hoth Therapeutics. “We are harnessing NVIDIA’s enterprise-grade AI infrastructure to accelerate the development of therapies like HT-001, HT-KIT, and our oncology programs — ultimately allowing us to make smarter, faster, and more precise decisions for patients.”
The NVIDIA AI Enterprise environment will allow Hoth’s scientific and data teams to:
-
Deploy predictive pharmacology and toxicity models to enhance compound screening efficiency.
-
Integrate multi-omic and patient-derived data for improved target discovery.
-
Support clinical trial simulation, patient stratification, and real-time response monitoring.
-
Leverage secure GPU-accelerated cloud infrastructure with enterprise-grade reliability and compliance.
Hoth’s AI initiative complements its broader strategy of digital transformation and innovation in biotechnology, enabling partnerships with advanced AI-driven platforms and life-science data companies to optimize development timelines, reduce costs, and improve therapeutic outcomes.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .